Cobalamin supplementation improves motor development and regurgitations in infants: results from a randomized intervention study

What Was Tested

This randomized controlled trial paper looks at Cyanocobalamin (Vitamin B12).

During infancy, minor developmental delays and gastrointestinal complaints are common, as is a biochemical profile indicative of impaired cobalamin status.

Who Took Part

The age groups tagged for this paper are infants, both men and women.

Infants <8 mo of age (n = 105) who were referred for feeding difficulties, subtle neurologic symptoms, or delayed psychomotor development were assessed for cobalamin status [by the measurement of serum cobalamin, plasma total homocysteine (tHcy), and plasma methylmalonic acid (MMA)].

How the Study Was Run

The design is described as randomized and double-blind.

Random assignment meant chance, not the researchers, decided who got Cyanocobalamin (Vitamin B12) and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Cyanocobalamin (Vitamin B12).

Motor function [Alberta Infants Motor Scale (AIMS)] and clinical symptoms (parental questionnaire) were recorded at entry and after 1 mo.

What Was Measured

During infancy, minor developmental delays and gastrointestinal complaints are common, as is a biochemical profile indicative of impaired cobalamin status.

Topics PubMed links to this paper include Biomarkers, Child Development, Dietary Supplements, Folic Acid, Homocysteine, Hydroxocobalamin and Linear Models.

What This Means in Plain Language

The paper is a randomized and double-blind study of Cyanocobalamin (Vitamin B12).

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2013 (The American journal of clinical nutrition), a journal based in United States.

More context: the Cyanocobalamin (Vitamin B12) compound page, all human trials.